Dopson-Troutt et al v. Novartis Pharmaceuticals Corporation

Filing 179

ORDER granting Defendant's 165 Motion to Enforce the Case Management Order. Signed by Judge Susan C Bucklew on 9/16/2013. (GMS)

UNITED STATES DISTRICT COURT
MIDDLE DISTRICT OF FLORIDA
TAMPA DIVISION
RUTH DOPSON-TROUTT and
FRANK TROUTT,
Plaintiffs,
v.

Case No.: 8:06-CV-1708-T-24-EAJ

NOVARTIS PHARMACEUTICALS
CORPORATION,
Defendant.
__________________________________________/
ORDER
This cause comes before the Court on Defendant Novartis Pharmaceuticals Corporation’s
Motion to Enforce the Case Management Order. [Doc. 165]. Plaintiffs Ruth Dopson-Troutt and
Frank Troutt filed a response in opposition, [Doc. 170], and NPC file a reply, [Doc. 173].
Argument was heard at the pretrial conference held on September 12, 2013.
I.

BACKGROUND FACTS
Plaintiff Ruth Dopson-Troutt was diagnosed with breast cancer, which later metastasized

to her hip and pelvic bones. Dr. Arthur Feldman, her oncologist, prescribed Aredia and Zometa,
which are bisphosphonate drugs that are produced, sold, and marketed by Defendant Novartis
Pharmaceuticals Corporation (“NPC”). From 1999 to 2005, Dopson-Troutt was infused with
Aredia and Zometa. After Dopson-Troutt had her tooth extracted, she began experiencing jaw
pain caused by osteonecrosis of the jaw (“ONJ”).
In 2006, Dopson-Troutt and her husband brought this action against NPC, alleging that
its manufacturing, labeling, marketing, selling, advertising, and distributing of Aredia and
Zometa caused their injuries and that NPC failed to, inter alia, adequately warn of the risk of

ONJ. This action was transferred to a Multidistrict Litigation Court in the Middle District of
Tennessee for consolidated pretrial proceedings with other actions brought against NPC. In July
2011, Dr. Feldman executed a sworn declaration. [Doc. 165, Exs. 2, 3].
In 2012, the case was remanded back to this Court. In the Court’s case management and
scheduling order, the Court set the discovery deadline for March 29, 2013 and jury trial for
October 2013. [Doc. 63]. In April 2013, the Court denied NPC’s motion for summary judgment
and made several Daubert rulings. [Docs. 110-114]. The Court also set the jury trial for a date
certain, on October 21, 2013. [Doc. 109]. Plaintiffs’ remaining claims are: negligent failure to
warn (count III), breach of express warranty (count IV), and loss of consortium (count VI).
[Docs. 1, 138].
On September 6, 2013, Plaintiffs issued a subpoena for and notice of a videotaped de
bene esse deposition of Dr. Feldman, set to occur on September 20, 2013.1 NPC seeks to strike
the notice of Dr. Feldman’s deposition as untimely, futile, and unfairly prejudicial.
II.

DISCUSSION
NPC seeks to strike the notice of Dr. Feldman’s deposition, because the deposition: (1) is

untimely and lacks good cause under the Court’s case management order; (2) would be futile,
given Dr. Feldman’s statements made in his declaration, which was obtained two years ago upon
the parties’ consent that his declaration would be acceptable in lieu of a deposition; and (3)
would be unfairly prejudicial because it any new facts would require NPC to change its trial
preparation efforts one month before trial.
In response, Plaintiffs state that they are seeking a de bene esse deposition to preserve
testimony for trial, not a discovery deposition, and therefore are permitted to take Dr. Feldman’s
deposition after the Court’s March 29, 2013 discovery deadline. Citing to Charles v. Wade, 665
1

At the pretrial conference, Plaintiffs’ counsel represented that Dr. Feldman has been served.

2

F.2d 661 (5th Cir. 1982), Plaintiffs assert that binding precedent provides that trial depositions
may be taken after the discovery deadline has passed to preserve testimony for trial.
However, Plaintiffs’ reliance on Charles for its apparent belief that it would be legal error
to treat de bene esse depositions as subject to the discovery deadline is misplaced.

The

determination is subject to the Court’s discretion, and while Charles held the district court
abused its discretion in denying the movant’s request to take a deposition for use at trial after the
discovery deadline had passed, Charles does not stand for the proposition that Plaintiffs have a
right to take Dr. Feldman’s de bene esse deposition one month prior to trial in this case.
In Chrysler International Corporation v. Chemaly, the Eleventh Circuit explained that in
allowing or disallowing a de bene esse deposition the district court should “consider all the
circumstances, including fairness to the adverse party and the amount of time remaining before
the date set for trial.” 280 F.3d 1358, 1362 (11th Cir. 2002). Chrysler affirmed the trial court’s
denial of the movant’s late request to take a de bene esse deposition, finding that:
Chrysler did delay in acting—by moving for the letter of request more than a year
after filing this lawsuit—to obtain the testimony of Sinclair in a form usable at
trial. The trial date was set. And . . . Chrysler had known that Sinclair resided on a
different continent and had known of the importance of Sinclair’s testimony for
some time: “as early as August 1999.”
Id. at 1361. Chrysler also distinguished its case facts from the facts in Charles:
[T]he reason given by the district court for denying permission to take the
deposition was simply that the discovery period had closed. Id. at 664. Nothing in
Charles suggests that the plaintiff delayed in setting the deposition of a known
witness. Also, at no time before the discovery period had closed had the district
court in Charles given any indication to the parties that it intended to treat all
depositions—whether for discovery or for use at trial—in the same fashion for
timing purposes. In addition, the potential deponent in Charles was an
incarcerated prisoner in an immediately adjoining state, not—as here—a free
businessman located on a different continent.
Id. at 1361.

3

Chrysler’s circumstances are similar to the facts here. Plaintiffs unduly delayed in acting
to obtain the Dr. Feldman’s deposition for use at trial. They have long known that Dr. Feldman
was a Pennsylvania resident, and nothing indicates that they were operating under the belief that
he would appear at trial. They have also known of the significance of his testimony. This is not
a case where Plaintiffs expected Dr. Feldman to provide trial testimony but Dr. Feldman later
became unavailable for an unforeseen reason. Neither Plaintiffs’ response motion nor oral made
at the pretrial conference provide a reason for their delay in seeking his deposition for the
purpose of preserving trial testimony.
Although the Court’s case management order does not distinguish between deadlines for
discovery and de bene esse depositions, neither do the Federal Rules of Civil Procedure. See
Fed. R. Civ. P. 32. It is not uncommon or inherently unreasonable for a court to treat discovery
deadlines as applying to all depositions. Chrysler, 280 F.3d at 162 n.8. Thus, in assuming that
the Court would draw a distinction, Plaintiffs “assume a risk: they cannot count on the []
[C]ourt’s allowing a deposition to be taken closer to the trial date.” Id.
Further, NPC contends Dr. Feldman’s de bene esse deposition would be unfairly
prejudicial because any new facts would require NPC to change its trial preparation efforts just
one month before trial. Plaintiffs’ denial that NPC would be unfairly prejudiced is insufficient to
show otherwise. Plaintiffs also assert that the primary reason for taking Dr. Feldman’s de bene
esse deposition is to preserve his testimony for trial in the event NPC objects to the admissibility
of Dr. Feldman’s declaration.

NPC negates this concern; in its reply and at the pretrial

conference, NPC represented to the Court that it would not object to the admissibility of Dr.
Feldman’s declaration. Moreover, Plaintiffs stated they nonetheless believe that their case “is
submissible under the law” without Dr. Feldman’s deposition. [Doc. 170, at 7].

4

Under the facts of this case—Plaintiffs’ undue delay in seeking to obtain Dr. Feldman’s
deposition, the timing of trial, unfairness to NPC, and NPC’s representation that it will not object
to the admissibility of Dr. Feldman’s declaration—the Court exercises its discretion and grants
NPC’s request to strike the notice of Dr. Feldman’s de bene esse deposition.
III.

CONCLUSION
Accordingly,

it

is

ORDERED

and

ADJUDGED

that

Defendant

Novartis

Pharmaceuticals Corporation’s Motion to Enforce the Case Management Order [Doc. 165] is
GRANTED.
DONE AND ORDERED in Tampa, Florida, this 16th day of September, 2013.

Copies to: Counsel of record and parties

5